TORONTO, Jan. 13 /CNW/ - GeneNews Limited (TSX: GEN), a company focused
on developing blood-based biomarker tests for the early detection of diseases
and personalized health management, today announced it has been granted U.S.
Patent No. 7,473,528 entitled "Method for the detection of Chagas disease
related gene transcripts in blood". This patent protects the Company's
discovery of a blood biomarker-based method of testing for Chagas disease, a
serious and potentially fatal disease resulting from parasitic infection.
Chagas disease is a significant public health issue affecting more than 11
million people worldwide each year.
"The Sentinel Principle(TM) technology is the basis of not only this
issued patent but also for the personalized health management system we are
developing which applies genomic information to monitor and address health
concerns on an individualized basis," stated Dr. Choong-Chin Liew, the
discoverer of the Sentinel Principle and Co-founder, Chief Scientist and
Director of GeneNews. "GeneNews has a broad array of pending patent
applications in diverse disease areas including oncology, cardiovascular,
neurological and inflammatory conditions," said Dr. Heiner Dreismann, Lead
Director and Interim CEO of GeneNews. "This is our first patent issuance based
on our Sentinel Principle platform technology and represents an important
initial milestone to realize commercial value from our pipeline of
discoveries." The Company currently has five issued patents and more than 70
pending patent applications, the majority of which are based on the
application of the Sentinel Principle.
GeneNews is focused on the application of functional genomics to enable
early diagnosis and personalized therapeutic intervention based on
disease-specific biomarkers. The Company has developed a novel approach, the
Sentinel Principle(TM), to detect and stage virtually any disease or medical
condition from a simple blood sample. GeneNews is currently applying the
Sentinel Principle(TM) in major areas with unmet clinical needs such as
cancer, arthritis, cardiovascular disease and neurological disorders. For more
information on GeneNews, visit www.genenews.com.
This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein. Investors should consult the Company's
ongoing quarterly filings and annual reports for additional information on
risks and uncertainties relating to these forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements. The
Company disclaims any obligation to update these forward-looking statements.
For further information:
For further information: James Smith, (416) 815-0700 x 229,